Switzerland· 67109003
Imbruvica 420 mg, Filmtabletten
A ibrutinib product, registered in Switzerland by Janssen-Cilag AG and dispensed under Swissmedic category A. The same ATC class is registered in 13 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Ibrutinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EL01 (ibrutinib), each read from that country’s own register.
- This record: Switzerland
- 8 of them publish a price we can compare per daily dose
Ibrutinib · ATC L01EL01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ibrutinib costs, country by country.
Normalised to the WHO defined daily dose (0.42 g), the median price runs from $4.92 in France to $193.73 in Switzerland — a ×39 gap.
- Switzerland: $193.73 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Ibrutinib · price per daily dose (0.42 g)
USD · FX 28 Sept 2026
- CH Switzerland$193.73
- FR France$4.92
The record
At a glance
- Manufacturer
- Janssen-Cilag AG
- Country
- Switzerland (CH)
- ATC code
- L01EL01
- ATC class
- Ibrutinib
- Defined daily dose
- 0.42 g, O
- Swissmedic category
- A
- Reimbursed
- No
- Last checked
- June 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
370 interactions on record for ibrutinib.
Graded by severity as the source publishes them — 189 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ibrutinib · interactions on record
370 records
- 189 severe
- 177 moderate
- 4 minor
Most severe, free to view
- AprepitantA04AD12severe
- LinseedA06AC05severe
- LonafarnibA16AX20severe
- DicoumarolB01AA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01EL01
Ibrutinib, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d7cd9305-0455-4238-bc3e-03b9f3cd9e39 GET /v1/drugs/d7cd9305-0455-4238-bc3e-03b9f3cd9e39?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Synthetika"
}See everything about ibrutinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.